III期-话题@MedSci

#III期#

681篇内容 | 2815人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594807, encodeId=c1d4159480e1a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=13, createdTime=2020-09-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594806, encodeId=4fff15948068b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=72, createdTime=2020-09-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594805, encodeId=02f81594805d6, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=74, createdTime=2020-09-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594804, encodeId=b1851594804f5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=17, createdTime=2020-09-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594803, encodeId=8900159480351, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, objectType=article, longId=201031, objectId=6a33201031d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a33201031d1, replyNumber=0, likeNumber=0, createdTime=2020-09-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a33201031d1, moduleTitle=ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a33201031d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594802, encodeId=b77e1594802f8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, objectType=article, longId=200935, objectId=015b2009357f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015b2009357f, replyNumber=0, likeNumber=51, createdTime=2020-09-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015b2009357f, moduleTitle=2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015b2009357f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594801, encodeId=6bce1594801c6, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验, objectType=article, longId=200903, objectId=43d720090395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d720090395, replyNumber=0, likeNumber=59, createdTime=2020-09-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d720090395, moduleTitle=韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d720090395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594800, encodeId=59bc159480043, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, objectType=article, longId=200854, objectId=2372200854b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2372200854b6, replyNumber=0, likeNumber=50, createdTime=2020-09-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2372200854b6, moduleTitle=NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2372200854b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594799, encodeId=eac11594e99d5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, objectType=article, longId=200768, objectId=614b200e686d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614b200e686d, replyNumber=0, likeNumber=76, createdTime=2020-09-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614b200e686d, moduleTitle=Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614b200e686d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594798, encodeId=f9a51594e9859, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, objectType=article, longId=200686, objectId=c99d2006862e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c99d2006862e, replyNumber=0, likeNumber=52, createdTime=2020-09-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c99d2006862e, moduleTitle=挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c99d2006862e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594797, encodeId=88f11594e9726, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, objectType=article, longId=200296, objectId=bd47200296fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd47200296fe, replyNumber=0, likeNumber=59, createdTime=2020-09-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd47200296fe, moduleTitle=Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd47200296fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594796, encodeId=99751594e965a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=200275, objectId=54442002e505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54442002e505, replyNumber=0, likeNumber=82, createdTime=2020-09-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54442002e505, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54442002e505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594795, encodeId=b7b61594e954b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=75, createdTime=2020-09-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594794, encodeId=6e111594e94ae, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, objectType=article, longId=200167, objectId=7b7b20016e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7b20016e1e, replyNumber=0, likeNumber=49, createdTime=2020-09-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7b20016e1e, moduleTitle=阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7b20016e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594793, encodeId=015d1594e9310, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, objectType=article, longId=200046, objectId=dd8a2000461b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd8a2000461b, replyNumber=0, likeNumber=56, createdTime=2020-08-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd8a2000461b, moduleTitle=Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd8a2000461b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594792, encodeId=da9e1594e9214, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, objectType=article, longId=200038, objectId=5362200038e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5362200038e5, replyNumber=0, likeNumber=101, createdTime=2020-08-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5362200038e5, moduleTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5362200038e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594791, encodeId=a0da1594e911d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, objectType=article, longId=200035, objectId=4a2d20003511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2d20003511, replyNumber=0, likeNumber=95, createdTime=2020-08-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2d20003511, moduleTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2d20003511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594790, encodeId=59f51594e9057, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, objectType=article, longId=199957, objectId=e37819995e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37819995e34, replyNumber=0, likeNumber=51, createdTime=2020-08-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37819995e34, moduleTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37819995e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594789, encodeId=8e371594e8948, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, objectType=article, longId=199865, objectId=756f199865ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f199865ac, replyNumber=0, likeNumber=76, createdTime=2020-08-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f199865ac, moduleTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f199865ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594788, encodeId=0be91594e88b5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, objectType=article, longId=199491, objectId=6d08199491a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d08199491a0, replyNumber=0, likeNumber=58, createdTime=2020-08-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d08199491a0, moduleTitle=NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d08199491a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验

2020-09-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2020-09-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2020-09-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2020-09-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ASCENT研究：全球Trop-2 ADC药物III期研究结果亮相

2020-09-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2020 ESMO：英飞凡治疗III期非小细胞肺癌迎来重大突破，约50％的患者获得了长达四年的生存期

2020-09-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

韩国MFDS批准抗COVID-19单克隆抗体CT-P59的II / III期关键试验

2020-09-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：贝利木单抗治疗活动性狼疮性肾炎III期临床获得成功

2020-09-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet Infect Dis：II价艰难梭菌疫苗III期临床研究失败

2020-09-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

挑战25年来的共识！阿尔兹海默症疫苗即将开展III期临床，这家公司剑指tau蛋白阿喀琉斯之踵

2020-09-16

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet：Vosoritide治疗儿童软骨发育不良III期临床获得成功

2020-09-07

智智灵药 (审核中...)

前往app查看评论内容

#III期#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2020-09-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-09-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康新冠疫苗计划在全球招募5万名志愿者，美国III期临床开启

2020-09-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Xerava（eravacycline）治疗复杂腹腔内感染：即将开展中国III期临床试验

2020-08-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性

2020-08-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展

2020-08-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利

2020-08-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验

2020-08-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Venetoclax治疗急性髓性白血病（AML），III期临床取得正面结果

2020-08-16

科室
- - 订阅+
  - 更多科室
工具
服务